Left to right: Kingson Lin, Kevin Rakin, Seth Herzon and Ranjit Bindra

By ex­ploit­ing the DNA re­pair sys­tem, Yale sci­en­tists want to crack chemother­a­py re­sis­tant brain can­cer

In 2005, Roger Stupp pub­lished an ar­ti­cle in NE­JM, show­ing that adding temo­zolo­mide to ra­dio­ther­a­py ex­tend­ed brain can­cer pa­tients’ sur­vival time by 2 months. For a can­cer in which me­di­an sur­vival was usu­al­ly less than a year, that was prac­tice-chang­ing.

Temo­zolo­mide would be added to the first line of chemother­a­pies for glioma pa­tients, and its use along­side ra­di­a­tion would be termed “The Stupp Pro­to­col.”

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.